Evofem's gel first non-hormonal contraceptive to get approval in over 30 years

By Dania Nadeem (Reuters) - Evofem Biosciences Inc's birth control gel received the U.S. Food and Drug Administration's approval on Friday, making it the first non-hormonal contraceptive for women in over three decades, sending its shares up 3.6%.

Reuters May 23, 2020 02:11:07 IST
Evofem's gel first non-hormonal contraceptive to get approval in over 30 years

Evofems gel first nonhormonal contraceptive to get approval in over 30 years

By Dania Nadeem

(Reuters) - Evofem Biosciences Inc's birth control gel received the U.S. Food and Drug Administration's approval on Friday, making it the first non-hormonal contraceptive for women in over three decades, sending its shares up 3.6%.

The company said earlier in May it was looking to price the contraceptive gel, Phexxi, between $250 and $275 for a box of 12 packs.

Phexxi's launch will, however, be delayed to the first week of September due to the disruptions caused by the coronavirus pandemic, the company said.

The gel is a rare new addition to the $5.5 billion U.S. contraceptive market, which is dominated by male condoms and hormonal birth control pills for women, known to cause a host of side effects such as bleeding between periods, mood swings and nausea.

The only non-hormonal contraceptive in the market has been the copper-based intrauterine devices, such as Cooper Surgical's ParaGard, which are often associated with bleeding and cramps, causing many to remove the implants within the first year.

The failure rate for male condoms is 13%, for hormonal pills it's 7% and less than 1% for intrauterine devices, according to the U.S. Centers for Disease Control and Prevention.

Clinical trials have found that Phexxi, which works by creating a hostile environment for the survival of sperm, has a 13.7% failure rate in preventing pregnancies.

The gel could bring in peak sales of $500 million by 2030, according to HC Wainwright analyst Raghuram Selvaju.

Phexxi, to be applied in the vagina using an applicator up to one hour before sex, has also been found to increase sexual satisfaction in female trial participants, likely due to the lubrication provided by the gel.

It is being studied for prevention of sexually transmitted diseases such as chlamydia and gonorrhea in women.

(Reporting by Dania Nadeem, Saumya Sibi Joseph and Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

GameStop to capitalize on 'stonks' rally with $1 billion stock sale plan
Business

GameStop to capitalize on 'stonks' rally with $1 billion stock sale plan

By Uday Sampath Kumar and Joshua Franklin (Reuters) - GameStop Corp on Monday increased the value of new stock it may sell from $100 million to $1 billion, as the U.S.

Gold flat as weak dollar counters rally in stocks
Business

Gold flat as weak dollar counters rally in stocks

By Shreyansi Singh (Reuters) - Gold prices were little changed on Monday as a softer dollar countered pressure from gains on Wall Street driven by hopes for a swift economic recovery following strong U.S. jobs data

Russia extends punitive Twitter slowdown until mid-May
Business

Russia extends punitive Twitter slowdown until mid-May

By Tom Balmforth and Alexander Marrow MOSCOW (Reuters) - Russia said on Monday it would extend a punitive slowdown of Twitter until May 15, though it acknowledged the U.S. social media company had speeded up deletion of what Moscow calls banned content. Moscow has traditionally taken a more hands-off role in policing the internet than neighbouring China.